SCHEMBL13536656

SCHEMBL13536656

CC(C)=CCC[C@@H](C)CCNC(Cc1c[nH]c2ccccc12)CN1CCCC1CO

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 4/20 0.39
BCHE P06276 3/20 0.39
CYP2C19 P33261 1/20 0.37
HTR1A P08908 1/20 0.37
DPP4 P27487 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PIN1 Q13526 1/20 0.37
SNCA P37840 2/20 0.37
IL1RN P18510 1/20 0.36
ERAP2 Q6P179 1/20 0.36
TACR1 P25103 1/20 0.36
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9906630 0.87 BCHE (0.40) HTR6BCHECYP2C19DPP4KDM4E
SCHEMBL9906627 0.84 HTR6 (0.38) HTR6CYP2C19HTR1ADPP4KDM4E
SCHEMBL9909028 0.84
SCHEMBL9906650 0.79 TDP1 (0.39) KMT2A
SCHEMBL9906616 0.70 SOS1 (0.39) HTR1AKMT2ASNCATACR1
SCHEMBL9906634 0.68 SPHK1 (0.37) KMT2A
SCHEMBL27191690 0.68 HTR1D (0.64) HTR6CYP2C19HTR1AKDM4EMAPT
SCHEMBL27191682 0.68 HTR1D (0.64) HTR6CYP2C19HTR1AKDM4EMAPT
SCHEMBL27191696 0.68 HTR1D (0.64) HTR6CYP2C19HTR1AKDM4EMAPT
SCHEMBL9909027 0.67 MEN1 (0.39) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652039-B2 Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis SEQUELLA, INC. (US) 2010-01-26 US disclosed
US-7652039-B2 Such as 1-(2-((3-(4-chlorophenoxy)benzyl)amino)-3-phenyl-propyl)piperidin-4-ol for treatment of tuberculosis; solid phase synthesis SEQUELLA, INC. (US) 2010-01-26 US disclosed